| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Hematology (Drs. Torn and Rosendaal) and Clinical Epidemiology (Dr. Rosendaal), Leiden University Medical Center; and Department of Neurology (Dr. Algra) and Julius Center for Patient Oriented Research (Dr. Algra), University Medical Center Utrecht, the Netherlands.
Address correspondence and reprint requests to Dr. F.R. Rosendaal, Department of Clinical Epidemiology, Leiden University Medical Center, C9-P. PO Box 9600, 2300 RC Leiden, the Netherlands; e-mail f.r.rosendaal{at}lumc.nl
Background: The use of oral anticoagulant therapy for the prevention of arterial thromboembolism in patients who have had ischemic stroke is controversial. Coumarins may increase the bleeding risk in patients with cerebral ischemia of arterial origin.
Objectives: 1) To calculate incidence rates of bleeding and thromboembolic events in patients with noncardiac cerebral ischemia who were treated routinely in an anticoagulation clinic. 2) To assess which factors contribute to the occurrence of events. 3) To determine the optimal intensity of oral anticoagulant therapy in these patients.
Methods: The authors studied all patients treated for noncardiac cerebral ischemia at the Leiden anticoagulation clinic between 1993 and 1998. Outcome events were major hemorrhage, major arterial thromboembolism, and death.
Results: The authors observed 356 patients for 644 patient-years. The incidence of major hemorrhage was 3.9 per 100 patient-years (95% CI, 2.5 to 5.7) and that of thromboembolism was 3.0 per 100 patient-years (95% CI, 1.8 to 4.6). The incidence of hemorrhage varied with the duration of treatment (relative risk [RR] of the first versus the second half-year, 3.8; 95% CI, 1.9 to 7.6), age (RR for age >65 years, 3.7; 95% CI, 1.1 to 12.3), and the intensity of oral anticoagulation (RR, 1.8 for each 0.5 international normalized ratio [INR] unit increase; 95% CI, 1.5 to 2.3). The optimal intensity of oral anticoagulant therapy was 2.5 to 3.5 INR; the best target value was 3.0 INR.
Conclusion: The risk of hemorrhage with anticoagulant therapy is high in patients with ischemic stroke of arterial origin but is mainly confined to early use and elderly patients.
This article has been cited by other articles:
|
|
 |
|
  M. Torn, S. C. Cannegieter, W. L. E. M. Bollen, F. J. M. van der Meer, E. E. van der Wall, and F. R. Rosendaal Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction: A Prospective Study of 4202 Patients Arch Intern Med, July 13, 2009; 169(13): 1203 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Oake MSc, A. Jennings MA, A. J. Forster MD MSc, D. Fergusson PhD, S. Doucette MSc, and C. van Walraven MD MSc Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis Can. Med. Assoc. J., July 29, 2008; 179(3): 235 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Oake, D. A. Fergusson, A. J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis Can. Med. Assoc. J., May 22, 2007; 176(11): 1589 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. van Walraven, N. Oake, P. S. Wells, and A. J. Forster Burden of Potentially Avoidable Anticoagulant-Associated Hemorrhagic and Thromobembolic Events in the Elderly Chest, May 1, 2007; 131(5): 1508 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Alemany, A. Stenborg, A. Terent, P. Sonninen, and R. Raininko Coexistence of Microhemorrhages and Acute Spontaneous Brain Hemorrhage: Correlation with Signs of Microangiopathy and Clinical Data Radiology, January 1, 2006; 238(1): 240 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, S. B. Tonarelli, and L. A. Pearce Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas Stroke, July 1, 2005; 36(7): 1588 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.H.A. Halkes and for the ESPRIT Study Group Oral Anticoagulation in Secondary Prevention After Cerebral Ischemia of Arterial Origin Stroke, May 1, 2005; 36(5): 933 - 933. [Full Text] [PDF]
|
|
|
|
|
|
M. Torn, F. J. M. van der Meer, and F. R. Rosendaal Lowering the Intensity of Oral Anticoagulant Therapy: Effects on the Risk of Hemorrhage and Thromboembolism Arch Intern Med, March 22, 2004; 164(6): 668 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
ESPRIT Oral Anticoagulation in Patients After Cerebral Ischemia of Arterial Origin and Risk of Intracranial Hemorrhage Stroke, June 1, 2003; 34 (6): e45 - e46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.G. Hennerici Editorial Comment: Low-Dose or Moderate-Dose Anticoagulation: Dream or Hope for Stroke Prevention? Stroke, June 1, 2003; 34 (6): e46 - e47. [Full Text] [PDF]
|
|
|
|
|
|
A. Algra, E.L.L.M. De Schryver, J. van Gijn, L.J. Kappelle, and P.J. Koudstaal Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin Stroke, January 1, 2003; 34(1): 234 - 235. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Hankey Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial: Is Warfarin Really a Reasonable Therapeutic Alternative to Aspirin for Preventing Recurrent Noncardioembolic Ischemic Stroke? Stroke, June 1, 2002; 33(6): 1723 - 1726. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Lewis, P. A.G. Sandercock, A. Algra, the European-Australian Stroke Prevention in Rever, D. H. Hsi, D. J. Alaimo, G. Butera, M. Chessa, M. Carminati, J.P. Mohr, et al. Warfarin or Aspirin for Recurrent Ischemic Stroke N. Engl. J. Med., April 11, 2002; 346(15): 1169 - 1171. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
